Literature DB >> 19641959

Catheter-directed thrombolysis for treatment of deep venous thrombosis in the upper extremities.

Anders Vik1, Pål Andre Holme, Kulbir Singh, Eric Dorenberg, Kåre Christian Nordhus, Satish Kumar, John-Bjarne Hansen.   

Abstract

Traditional anticoagulant treatment of deep venous thrombosis (DVT) in the upper extremities (UEDVT) is associated with a relatively high incidence of postthrombotic syndrome (PTS). Catheter-directed thrombolysis (CDT) for UEDVT would provide efficient thrombolysis with less subsequent PTS than during traditional anticoagulation. Primary efficacy, complications, and long-term results after CDT are reported in a retrospective cohort (2002-2007) of patients (n = 30) with DVT in the upper extremities. PTS was assessed by a modified Villalta scale. UEDVT was unprovoked in 11 (37%) cases and effort related in 9 (30%) cases. The median duration of symptoms prior to CDT was 7.0 days (range, 1-30); median duration of thrombolysis treatment, 70 h (range, 24-264 h); and the median amount of rt-PA infused during CDT, 52 mg (range, 19-225 mg). Major bleeding was registered in three (9%) patients, and CDT was stopped prematurely in three patients due to local hematoma. No intracerebral bleeding, clinical pulmonary embolism, or deaths occurred during treatment. Grade II (>50%) or III (>90%) lysis was present in 29 patients (97%) at the end of CDT. Bleeding complications increased by each day of delay from the debut of symptoms to the start of treatment (OR, 1.20; 95% CI, 1.01-1.42). At follow-up (n = 29; median, 21 months; range, 5-58 months), 11 (38%) patients had occluded veins, whereas 18 (62%) had patent veins. However, stenosis of varying severity was present in eight of those with a patent vein. No patients had severe PTS, whereas six (21%) experienced mild PTS. In conclusion, our retrospective cohort study of patients with UEDVT showed that treatment restored venous drainage, with a subsequent low frequency of mild PTS at follow-up. Early intervention with CDT prevented bleeding complications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19641959     DOI: 10.1007/s00270-009-9655-y

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  7 in total

1.  Paget-Schrotter syndrome and complications of management.

Authors:  A Dep; E Concannon; S M Mc Hugh; P Burke
Journal:  BMJ Case Rep       Date:  2013-07-12

2.  Catheter-related thrombosis (CRT) in patients with solid tumors: a narrative review and clinical guidance for daily care.

Authors:  Juan Carlos Laguna; Tim Cooksley; Shin Ahn; Nikolaos Tsoukalas; Thein Hlaing Oo; Norman Brito-Dellan; Francis Esposito; Carmen Escalante; Carme Font
Journal:  Support Care Cancer       Date:  2022-08-06       Impact factor: 3.359

3.  Upper extremity deep vein thrombosis.

Authors:  Sanjith Saseedharan; Sunil Bhargava
Journal:  Int J Crit Illn Inj Sci       Date:  2012-01

4.  Recurrent Upper Extremity Thrombosis Associated with Overactivity: A Case of Delayed Diagnosis of Paget-Schroetter Syndrome.

Authors:  Himani Sharma; Abhinav Tiwari
Journal:  Case Rep Vasc Med       Date:  2017-07-10

5.  Early outcomes using dedicated venous stents in the upper limb of patients with venous thoracic outlet syndrome: A single centre experience.

Authors:  Saissan Rajendran; Tommy Y Cai; Jacky Loa; Prakash Saha; Steven Dubenec
Journal:  CVIR Endovasc       Date:  2019-07-18

6.  Pharmacomechanical thrombolysis in the management of paget-schroetter syndrome.

Authors:  Elli Papantoniou; Luke Morgan-Rowe; Edward Johnston; Duncan Brennand; Jowad Raja; Julian Hague
Journal:  Case Rep Radiol       Date:  2013-02-11

7.  A Retrospective Comparison of Ultrasound-Assisted Catheter-Directed Thrombolysis and Catheter-Directed Thrombolysis Alone for Treatment of Proximal Deep Vein Thrombosis.

Authors:  Vladimir Y I G Tichelaar; Ellen E Brodin; Anders Vik; Trond Isaksen; Finn Egil Skjeldestad; Satish Kumar; Nora C Trasti; Kulbir Singh; John-Bjarne Hansen
Journal:  Cardiovasc Intervent Radiol       Date:  2016-06-01       Impact factor: 2.740

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.